Sensei Biotherapeutics Inc

Item 5. Other Information.

Rule 10b5-1 Trading Plans

From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading plans (as each such term is defined in Item 408 of Regulation S-K). The trading plans are intended to satisfy the affirmative defense in Rule 10b5-1(c). During the three months ended June 30, 2024 our officers and directors took the following actions with respect to 10b5-1 trading plans:

On June 6, 2024, Cambrian BioPharma, Inc., a beneficial owner of more than 5% of the Company’s outstanding shares of common stock (“Cambrian”) entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Cambrian 10b5-1 Plan”). James Peyer, a director of the Company, is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian’s board of directors. The Cambrian 10b5-1 Plan commenced on June 6, 2024, and willrun through December 10, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Cambrian 10b5-1 Plan is up to 195,000 shares.